Evoke Pharma said that the United States Patent and Trademark Office (USPTO) has issued US patent No. 11,020,361 (“Nasal Formulations of Metoclopramide”) covering methods of use for Gimoti metoclopramide nasal spray for the treatment of gastroparesis until at least 2029. The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020.
Evoke President and CEO Dave Gonyer commented, “We are pleased to announce the issuance of this new US patent which further validates that Gimoti is innovative and novel. We believe Gimoti provides a new and effective option for treating patients that have erratic absorption of oral medications, as it is the first and only outpatient non-oral treatment to help improve the quality of life for patients suffering with diabetic gastroparesis. The issuance of this patent strengthens the intellectual property protection for Gimoti and supports our commercial efforts to make Gimoti the treatment of choice in the gastroparesis market.”
Read the Evoke Pharma press release.
